Ann: Updated Strategy and Investor Presentation, page-243

I don't know - that's why I asked if they're going to track it.

Regardless, these side effects might not even be considered significant enough to impact 'Quality of Life' (as per whatever definition the FDA have used for 'Optimus') - that's why I asked that too.

One of the stated goals of Project Optimus includes maximising 'tolerability' (https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus)

But how 'tolerability' is defined is a little unclear; in fact there's even a study on the use of the term 'tolerability' here: https://pubmed.ncbi.nlm.nih.gov/34342031/

If tolerability is a measure of '...subjective patient-reported symptoms' then I suspect incidence of nausea, sickness and alopecia might be significant considerations for a patient asked by their clinician how well they're tolerating a drug.

If it's on a more objective analysis, then perhaps not.

Either way, this is not a reason to influence go or no-go trial decisions (and certainly isn't as headline grabbing or as commercially relevant as cardioprotect)

I was just curious - bisantrene has a habit of demonstrating benefits previously overlooked/not understood.